Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01752985 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
NCT01752985: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01752985 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 319 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (140% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01752985, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
Primary Outcome
The presence of albumin in the urine (macroalbuminuria) is a marker of kidney disease. Albumin and creatinine concentrations were obtained from spot urine samples. UACR was calculated as the geometric mean of two first-morning void urine UACR measurements with samples collected on two separate occasions within a 4-day period.
Interventions
- DRUG BMS-813160
- DRUG Placebo matching with BMS-813160
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2015-06-30 |
| Phase | Phase 2 |
Why NCT01752985 stopped before completion
NCT01752985 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (140% higher).
The record links to 0 conditions, and to 2 interventions - of which BMS-813160 is the first listed.
NCT01752985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01752985 about?
NCT01752985 is a clinical study titled "Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease". The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
What is the current status of trial NCT01752985?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2013-03-18. Estimated completion is 2015-06-30.
What interventions are being tested in trial NCT01752985?
The interventions under investigation include: BMS-813160 (DRUG), Placebo matching with BMS-813160 (DRUG).
Who is sponsoring clinical trial NCT01752985?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01752985's enrollment target sits among peer trials
319 153rd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI